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Abstract: Background: Although the relation of the gut microbiota to a development of autoimmune
and inflammatory diseases has been investigated in various animal models, there are limited studies
that evaluate the effect of probiotics in the autoimmune eye disease. Therefore, we aimed to
investigate the effect of IRT-5 probiotics consisting of Lactobacillus casei, Lactobacillus acidophilus,
Lactobacillus reuteri, Bifidobacterium bifidum, and Streptococcus thermophilus on the autoimmunity
of uveitis and dry eye and alloimmunity of corneal transplantation. Methods: Experimental
autoimmune uveitis was induced by subcutaneous immunization with interphotoreceptor-binding
protein and intraperitoneal injection of pertussis toxin in C57BL/6 (B6) mice. For an autoimmune dry
eye model, 12-weeks-old NOD.B10.H2b mice were used. Donor cornea of B6 mice was transplanted
into BALB/C mice. IRT-5 probiotics or phosphate buffered saline (PBS) were administered for three
weeks immediately after induction of uveitis or transplantation. The inflammation score of the
retinal tissues, dry eye manifestations (corneal staining and tear secretion), and graft survival were
measured in each model. The changes of T cells were evaluated in drainage lymph nodes using
fluorescence-activated cell sorting. Results: Retinal histology score in IRT-5 group of uveitis was
lower than that in PBS group (p = 0.045). Ocular staining score was lower (p < 0.0001) and tear
secretion was higher (p < 0.0001) in the IRT-5 group of NOD.B10.H2b mice than that in the PBS
group. However, the graft survival in the IRT-5 group was not different from those of PBS group.
The percentage of regulatory T cells was increased in the IRT-5-treated dry eye models (p = 0.032).
The percentage of CD8+IL-17hi (p = 0.027) and CD8+ interferon gamma (IFNγ)hi cells (p = 0.022) were
significantly decreased in the IRT-5-treated uveitis models and the percentage of CD8+IFNγhi cells
was markedly reduced (p = 0.036) in IRT-5-treated dry eye model. Conclusion: Our results suggest
that administration of IRT-5 probiotics may modulate clinical manifestations of autoimmunity in the
eye, but not on alloimmunity of corneal transplantation.
Keywords: autoimmunity; alloimmunity; cornea; dry eye; experimental autoimmune uveitis; IRT-5
probiotics; immunomodulatory effect; transplantation
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1. Introduction
Advances in genomic sequencing in gut microbiota have revealed the possible relationship of human
disease and immune homeostasis with the gut microbiota [1,2]. The contribution of the commensal
or pathogenic microbiota of the gut to a development of autoimmune and inflammatory diseases has
been investigated in various animal models of demyelinating disease, inflammatory bowel disease and
autoimmune uveitis [3–5]. In addition, the gut microbiota is reported to act as a key player in balancing
immune responses between regulatory T (Treg) cells and Th17 cells at mucosal surfaces [6,7].
Probiotics are live microorganisms that can provide beneficial effects on the host organism
by competing with potential pathogens or gut commensals [8]. Probiotics can induce tolerance or
modification of the immune system for the use of biotherapy [8,9]. Recent studies have shown the
Lactobacilli and Bifidobacterium-specific beneficial effect in modifying inflammation in rheumatoid
arthritis (RA), inflammatory bowel disease (IBD) and atopic dermatitis (AD) [10–12]. IRT-5 probiotic
formulation has immune-modulatory effects in a model of experimental autoimmune myasthenia
gravis (MG), colitis, and experimental autoimmune encephalomyelitis (EAE) models, by modifying T
cell responses or Treg-Th17 homeostasis [13–15].
Autoimmune dry eye related to Sjögren’s syndrome, systemic lupus erythematosus (SLE) and
rheumatoid arthritis are a chronic, devastating and incurable disease. Autoimmune uveitis is also
a chronically deteriorating disease that disturbs visual acuity. If non-drug biotherapy can modify
disease to render it less reactive, a steroid-related complication may be lessened. Emerging evidence
suggest that gut microbiota may trigger autoimmunity in SLE, Sjögren’s syndrome and autoimmune
uveitis with autoreactive T cells [16–18]. Therefore, the purpose of the study was to investigate
whether IRT-5 probiotics could have an effect on autoimmunity of experimental uveitis or dry eye by
modulating autoreactive T cells. We also tried to determine whether IRT-5 related reaction was specific
to autoreactive T cells or non-specifically suppressed both autoreactive and alloreactive T cells in the
corneal transplantation model.
2. Materials and Methods
2.1. Animals
All the animals were managed in accordance with the Association for Research in Vision
and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research.
The study protocols were approved by the Institutional Animal Care and Use Committee of Seoul
National University Biomedical Research Institute (IAUCUC No. 15-0124-C1A0 and IAUCUC
No. 15-0136-C1A0).
Six-week-old female B6 (C57BL/6J) mice and BALB/C mice were purchased from Orient Bio Inc.
(Seongnam, Korea). B6 mice were used for the experimental autoimmune uveitis (EAU) model and the
B6-to-BALB/C model was used in corneal allo-transplantation. Breeding pairs of non-obese diabetic
NOD.B10.H2b mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA) for breeding,
and male NOD.B10.H2b mice were used for the autoimmune dry eye model. All the mice were
bred under a specific pathogen-free environment and maintained at 22 ◦C–24 ◦C, relative humidity
55% ± 5%, with free access to water and food at the Mouse Facility at Biomedical Research Institute
of Seoul National University Hospital. All the mice were pre-treated with combined antibiotics
(ampicillin, 1 g/L; vancomycin, 500 mg/L; and metronidazole, 1 g/L; all from Sigma-Aldrich, St. Louis,
MO, USA) in drinking water for 5 days before an oral gavage of IRT-5 (treated group) or phosphate
buffered saline(PBS, control) to promote settlement of IRT-5 probiotics in the intestine.
2.2. Preparation of the Probiotic Mixtures of IRT-5
Probiotic IRT-5 (consisting of L. casei, L. acidophilus, L. reuteri, B. bifidum, and S. thermophilus)
powder contains 2 × 108 colony forming units (CFU)/g of each strain [13,14]. The total amounts of
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IRT-5 probiotics were 1 × 109 CFU in 300 µL PBS per mice for an oral gavage feeding [13,14]. All the
probiotic strains were kindly provided by Korea Yakult Co. (Giheung, Korea).
2.3. Induction and Treatment of EAU
EAU was induced in B6 mice using the method as previously described [19]. Briefly, after
pretreatment of antibiotics, 250 µg of human interphotoreceptor retinoid-binding protein(IRBP) peptide
1–20, GPTHLFQPSLVLDMAKVLLD (20 mg/mL; Peptron, Daejeon, Korea), emulsified in complete
Freund adjuvant (Sigma) which contains Mycobacterium tuberculosis (2.5 mg/mL; BD DifcoTM,
Franklin Lakes, NJ, USA) were injected into a footpad. Concurrently, the mice received 0.7 µg Pertussis
toxin (300 µL; Sigma-Aldrich, St. Louis, MO, USA) intraperitoneally. Immediately after immunization,
either 1 × 109 IRT-5 probiotics in 300 µL PBS (n = 11) or 300 µL PBS (n = 10) alone was gavaged orally
once a day for 3 weeks. Unimmunized B6 mice were used for negative control (n = 6). After 3 weeks of
the treatment, the mice were sacrificed for the assay.
2.4. IRT-5Treatment in Autoimmune Dry Eye Model
Twelve-week-old male NOD.B10.H2b mice were used as the autoimmune dry eye model (n = 31).
Either 1 × 109 IRT-5 probiotics in 300 µL PBS (n = 16) or 300 µL PBS (n = 15) alone was gavaged orally
once a day for 3 weeks after pre-treatment of antibiotics. After 3 weeks of the treatment, the mice were
sacrificed for the assay.
2.5. Corneal Transplantation and IRT-5Treatment
After pre-treatment of antibiotics, full-thickness penetrating orthotopic corneal grafts were
transplanted as previously described [20,21] with a few modifications. Seven-week-old B6 mice
(H-2b) were served as corneal donors, and BALB/c mice (H-2d) used as recipients (allografts; n = 22).
Donor corneal buttons (2.5 mm-diameter) were transplanted in a 2.0 mm host trephined-bed and
sutured in place with six to eight interrupted 10-0 nylon sutures (Ethicon, Somerville, NJ, USA).
Either 1 × 109 IRT-5 probiotics in 300 µL PBS (n = 14) or 300 µL PBS (n = 8) alone was gavaged orally
once a day for 3 weeks in allografted mice. Syngeneic corneal grafts (BALB/c-to-BALB/c) were
also performed as negative controls (n = 6). After the surgery, all recipients received antibiotic eye
drops (levofloxacin, Cravit®, Santen Pharmaceutical Co., Ltd., Osaka, Japan) once a day from the day of
surgery (postoperative day, POD 0) for 14 days. All grafts were evaluated twice per week for 3 weeks.
Graft rejection, defined as complete loss of graft transparency as mentioned in the previous study [22]
was evaluated in a blinded manner. After 3 weeks of the treatment, the mice were sacrificed for the assay.
2.6. Evaluation of Clinical Manifestations in Autoimmune Dry Eye Model
Under anesthesia with zoletil and xylazine, phenol red-impregnated cotton threads (FCI
Ophthalmics, Pembroke, MA, USA) were administered into the lateral canthus of mice for 60 s,
and wetting of the thread was measured in millimeters to evaluate the amount of tear production.
For corneal epithelial defect observation, one drop of 3% Lissamine Green B (Sigma-Aldrich) was
applied to the lower lateral conjunctival sac because it has convenience not requiring cobalt light
excitation [23] under anesthesia. Dye staining of the cornea was scored in a blinded manner as follows:
score 0 for no punctuate staining; score 1 when less than one-third of the cornea was stained; score 2
when two-thirds or less was stained; and score 3 when more than two-thirds were stained.
2.7. Histology and Histological Scoring of EAU
On day 21 after immunization, the mice were euthanized by cervical dislocation after being
anesthetized with zoletil, according to the American Veterinary Medical Association Guidelines for
the Euthanasia of Animals (2013 Edition), and the eyeballs were harvested for the histopathologic
examination. Eyeballs were fixed in 10% formaldehyde and paraffin-embedded. Serial 4-µm-thick
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sections were sliced and stained with hematoxylin and eosin (H&E). The histologic features were
observed, and pathology scores were graded in a blinded manner on a scale of 0 to 4 according to the
criteria previously described by Caspi [24].
2.8. Histopathology of ExtraorbitalGland in Autoimmune Dry Eye Model
The extraorbital gland was excised and fixed in 10% formalin. The samples were sliced into
4-µm-thick sections and stained using H&E. Inflammatory foci score (>50 inflammatory cells/focus = 1,
25–50 inflammatory cells/focus = 0.5) was measured in a blinded manner.
2.9. Flow Cytometry Analysis of T CellSubsets
Cervical lymph nodes were collected in mice of uveitis (n = 3–6) and transplantation model
(n = 6–11), and submandibular lymph nodes (n = 5) were collected in the mice of autoimmune dry eye
model. The proportions of Th1, Th17, or Treg cells were determined by measuring IFN-γ, IL-17, or CD25
and Foxp3-expressing CD4+T cells using flow cytometry. To collect cell suspensions, lymph nodes were
placed and minced between the frosted ends of two glass slides in RPMI media containing 10% fetal
bovine serum (FBS) and 1% penicillin-streptomycin. The cells were immunostained using the following
fluorescence-conjugated anti-mouse antibodies: CD4, CD25, Foxp3, IFNγ, major histocompatibility
complex (MHC) II, CD11b, Ly6G and Ly6C (all from eBioscience, San Diego, CA, USA) and interleukin
(IL)-17A (BD Pharmingen™, San Diego, CA, USA). For intracellular staining, the cells were stimulated
for 4 h with 50 ng/mL phorbolmyristate acetate and 1 µg/mL ionomycin in the presence of GolgiPlug
(BD Pharmingen™). The fluorescence assays of the cells were performed using a FACSCanto flow
cytometer (BD BioSciences, Mountain View, CA, USA). The gate was set on CD4+ cell population, and
further analysis of surface or intracellular markers was done within this gate. Gating strategies are
shown in Supplementary Figure S1. For the gating of Treg cells, the gate was set on CD4 cells, and
further gated with CD25hi and FoxP3hi cells. For the gating of monocytic Myeloid-Derived Suppressor
Cells (mMDSC), the gate was set on MHCloCD11bhi cell population, and further gated with Ly6Glo
and Ly6Chi cells. Data were analyzed using the FlowJo program (Tree Star, Inc., Ashland, OR, USA).
2.10. Statistical Analysis
All statistical tests were performed using Prism software (GraphPad Prism, Inc., La Jolla,
CA, USA). Data were analyzed by one-way analysis of variance (ANOVA) or Dunnett’s multiple
comparisons tests to compare more than two groups. Independent t-test or nonparametric
Mann–Whitney U test was used for a comparison of two groups. To compare the changes over
time, data were analyzed by paired t-test or Wilcoxon matched-pairs signed rank test. The survival
was compared using the Log–Rank test. The data are presented as the mean ± standard error (SE).
Differences were considered significant at p < 0.05.
3. Results
3.1. IRT-5Treatment Prevents Development of EAU
We first evaluated whether daily oral gavage of IRT-5 could diminish inflammation in
autoimmunity using EAU model of the B6 mouse. After 3 weeks treatment with IRT-5, disruption
of photoreceptor layer was barely observed with few inflammatory cells. On the contrary, severe
destruction of the photoreceptor layer was found with many inflammatory cells present in PBS-treated
mice (Figure 1A). Histology score in IRT-5-treated mice was lower than in PBS-treated mice (p = 0.045,
one-way ANOVA and Dunnett’s multiple comparisons test, Figure 1B). Flow cytometry of cervical
lymph nodes showed that the percentage of CD8+IL17hiand CD8+IFNγhi cells in IRT-5-treated mice
were lower than in PBS-treated mice (p = 0.027 and p = 0.022, respectively; one-way ANOVA and
Dunnett’s multiple comparisons test). There were no significant differences regarding the percentage
of IFNγ or IL-17 secreting CD4+ T cells and mMDSC. Unexpectedly, the percentage of Treg cells was
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higher in the uveitis model than in control (p = 0.0021), while the percentage of Treg cells was lower
in IRT-5-treated mice than in PBS-treated mice (p = 0.0021, one-way ANOVA and Dunnett’s multiple
comparisons test). This suggests that the modulation of autoreactive CD8+ T effector cells with IRT-5
seems not to be mediated by Treg cells in uveitis model.
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Figure 1. IRT-5 treatment suppresses inflammation of experimental autoimmune uveitis (EAU).
(A) Hematoxylin and eosin (H&E) staining of cross-sections of retinal tissues. Disruption of
photoreceptor layer and diffuse infiltration of inflammatory cells into the outer nuclear layer (boxes
indicate inflammation foci) were remarkably reduced with few inflammatory cells in IRT-5-treated one.
INL: inner nuclear layer, ONL: outer nuclear layer, PR: photoreceptor layer; (B) Histology score was
lower in IRT-5-treated mice than in phosphate buffered saline(PBS)-treated mice (p = 0.045, one-way
ANOVA and Dunnett’s multiple comparisons test); (C) Data depict the percentage of IFNγ or IL-17
secreting T cells, CD4+CD25+Foxp3hiT regulatory cells, and mMDSC among the total cervical lymph
node(CLN) cells (* p < 0.05; ** p < 0.01; one-way ANOVA and Dunnett’s multiple comparisons test).
The percentage of CD8+IL17hi (p = 0.027) and CD8+IFNγhicells (p = 0.022) in IRT-5-treated mice were
lower than in PBS-treated mice. The percentage of Treg cells was higher than in control (p = 0.0021),
while it was lower in IRT-5-treated mice than in PBS-treated mice (p = 0.0021). Data are presented as
mean ± standard errors.
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3.2. IRT-5 Treatment Attenuates Clinical Manifestations of Autoimmune Dry Eye Models
In parallel, we assessed whether daily oral gavage of IRT-5 could be also effective in reduction
of autoimmune dry eye manifestation using 12-week-old NOD.B10.H2b mice in the Sjögren’s disease
model. Surprisingly, IRT-5 treatment reduced ocular staining (p < 0.0001, paired t-test) and increased
tear secretion (p < 0.0001, paired t-test; Figure 2A–C). Flow cytometry of draining lymph nodes
(submandibular LN) revealed that the percentage of CD8+IFNγhi cells in IRT-5-treated mice were
lower than in PBS-treated mice (p = 0.036, Mann–Whitney U test), which was accompanied by the
increased Treg cells in IRT-5-treated mice (p = 0.032, Mann–Whitney U test, Figure 2D). The percentage
of mMDSC was not changed with IRT-5 treatment. H&E cross-sections of extraorbital glands show
few inflammation foci in IRT-5-treated mice than in PBS-treated mice with a marginal significance
(p = 0.067, Mann–Whitney U test; Figure 3A,B). It indicates that Treg cells may be involved in the
induction of tolerance in autoimmune dry eye model with IRT-5 treatment.
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Figure 2. IRT-5 treatment reduces clinical manifestations of autoimmune dry eye model. (A) One set 
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Figure 2. IRT-5 treatment reduc s clinical manifestatio autoi mune dry eye model. (A) One set of
the representative photos for the ocular staining scoring; (B) Ocular staining score was significantly
decreased compared with the score of pretreated level in IRT-5-treated mice (*** p < 0.0001, paired
t-test); (C) Phenol red thread test showed significant increase of tear secretion in IRT-5-treated
mice(*** p < 0.0001, paired t-test); (D) Data depict the percentage of IFNγ or IL-17 secreting T cells,
CD4+CD25+Foxp3hi T regulatory cells, and mMDSC among the total draining lymph node(DLN) cells
(* p < 0.05, Mann–Whitney U test). The percentage of CD8+IFNγhi cells in IRT-5-treated mice was lower
than in PBS-treated mice (p = 0.036). The percentage of Treg cells was higher in IRT-5-treated mice were
lower than in PBS-treated mice (p = 0.032); Data are presented as mean ± standard errors.
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Figure 3. IRT-5 treat ent atten ates inflammation of autoi mune dry eye models (A) One set of
representative H&E cross-sections of extraorbital glands (upper panel; PBS-treated one, lower panel;
IRT-5-treated one, arrows indicate inflammation foci which include more than 50 inflammatory cells);
(B) Inflammation foci score is lower in IRT-5-treated mice than in PBS-treated mice with a marginal
significance (p = 0.067, Mann–Whitney U test). Data are presented as mean ± standard errors.
3.3. IRT-5Treatment Does Not Prolong the Survival of Corneal Allograft
Finally, we investigated whether the immunomodulatory effect of IRT-5 treatment could
affect alloimmunity in B6-to BALB/C transplantation model. However, survival curve shows no
prolongation of the corneal allografts in IRT-5-treated (p = 0.3413, Log-Rank test; Figure 4B). There were
no significant changes of IFNγ or IL-17 secreting effector T cells, Treg cells, and mMDSC in cervical
lymph nodes between IRT-5- and PBS-treated mice (Figure 4C). It suggests that IRT-5 treatment
cann t suppress all immunity associated inflammation albeit it can suppress autoimmunity associated
inflammation, which means treatment of IRT-5 is specific to autoimmunity.
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transplanta ion model. ( tative photographs of the cornea at day 22; (B) Survival curve
of corneal allograft shows no statistical differ nce b tween in IRT-5-tre ted and PBS-treat d mice
(p = 0. 413, Log-Rank test); (C) Data depict th percentage of IFNγ or IL-17 s creting T cells,
CD4+CD25+Fox r , and mMDSC among the total DLN cells (* p < 0.05, one-way NOVA
and Dunnett’s multiple comparisons test). There are no sig ificant differences of T effector cells, Treg
cells and mMDSC between in IRT-5-treated and PBS-treated mice.
4. Discussion
Herein, we report that oral application of IRT-5 probiotics attenuates clinical disease of EAU
and autoimmune dry eye by reducing autoreactive T cells. IRT-5 does not influence alloimmunity
of corneal transplantation. As far as us aware of, this is the first report describing probiotics can be
effective in attenuating autoimmune uveitis or autoimmune dry eye. The immune modulatory effect
on ocular autoimmune disease well corresponds with the experimental outcome with IRT-5probiotics
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in the other autoimmune disease, such as MG, colitis, and EAE of previous reports [13–15]. The present
data indicate that autoreactive T cells in EAU and dry eye may be cross-reactive to the gut antigen,
while alloreactive T cells in corneal transplantation are not cross-reactive. Given that the severity of
Sjögren’s syndrome is correlated with microbial dysbiosis [25], our study suggests a clinical relevance
that IRT-5 may be beneficial in the patients with Sjögren’s syndrome. Since most of the study groups
included less than 10 mice, further studies using larger numbers of animals would be required to
clarify the results.
Probiotics have been investigated in clinical trials to prove their efficacy [26–28]. A meta-analysis
regarding the effect of probiotics on the maintenance of remission in ulcerative colitis reported
that relapse was lower in probiotic patients at one year than in placebo patients (Odds Ratio 0.27),
suggesting a positive effect [28]. A double-blind, randomized, placebo-controlled trial with sixty
children with perennial allergic rhinitis showed no additional benefit of Lactobacillus paracasei when
used with regular levocetirizine, although there was a continuing decrease in symptomatic scores [27].
While, a prospective, open-label phase I/II controlled clinical trial with forty subjects with an ocular
dysesthesia and comorbid enteral and anxiety-depression symptoms showed significant improvement
of the symptoms in treated group with probiotic lysate as compared to the control group. This study
suggests that probiotics may work on the ocular disease. Overall, the effect of probiotics appears to be
dependent on the clinical disease entities or the applied microorganism strains. Through the emerge of
the evidence, Lactobacillus and Bifidobacterium are known to be one of the key players in producing
immune modulatory molecules or Treg cells [10,12,29]. However, the exact underlying mechanism of
probiotics on human immune system remains unexplored.
Regarding the IRT-5 probiotics used in this study, five strains exhibiting high secretion of IL-10
and low secretion of IL-12 in the ex vivo co-culture system with immune cells were selected by
the collaborator (S.H. Im) [29,30]. The IRT-5 mixture includes both Lactobacillus and Bifidobacterium.
The mode of action of IRT-5 probiotics is still unclear, and its efficacy seems to differ depending on the
underlying autoimmune disease or recipient mouse strain as similar to other probiotics. Nevertheless,
the mixture of multiple strains is regarded to be synergistic, with enhanced survival in the intestine
compared with a single strain [29].
Understanding the pathogenesis of autoimmune ocular diseases, such as uveitis and Sjögren’s
syndrome, is imperative to develop the therapeutic intervention. Etiologies of uveitis and dry eye
are heterogeneous and there is no single animal model. However, the evidence is emerging that T
cell-targeted therapy can be used to treat both diseases [31]. Th17 cells and IL-17 are known to be one
of the key players in both diseases [5,32]. The role in CD8+T cells in autoimmune disease is debatable.
One study reported CD8+T cells may attenuate dry eye by decreasing IL-17A producing cells in the B6
mouse model [33]. Another study described that autoimmunity can be also induced by antigen-specific
CD8+T cells in the model of uveitis, albeit CD4+T cell-driven disease being dominant [34]. In this
regard, it can be presumed that autoreactive CD8+ T cells may be cross-reactive to gut antigen in this
uveitis model, and the decrease of CD8+IL17hi and CD8+IFNγhi cells in IRT-5-treated mice of our
study may contribute to the prevention of uveitis. Clinical symptoms in keratoconjunctivitis sicca in
both Sjögren’s syndrome and non-Sjögren dry eye are also known to be dependent on T cell activation,
both CD4+ and CD8+T cells [35–37]. In Sjögren’s syndrome, pathogenesis relating to microorganism
are proposed as follows [38]; (1) autoreactive T cells against Ro-60 could be activated by the peptides
from oral, skin and gut bacteria; (2) immature B cells may not be appropriately removed to increase
autoreactive B cells by failing access to gut-associated lymphoid tissue; (3) Ro-60 activated T cells
could activate autoreactive B cells; and (4) dysbiosis of the gut microbiota could increase Th17 cells
to migrate systemic circulation. With this line of reasoning, it is conceivable that the IRT-5 probiotics
might suppress cross-reactive T cells against gut peptides in this dry eye model, and therefore it might
make the clinical manifestation improved.
Considering that Th17 cells may be more effective than Th1 cells to promote B cell proliferating
and differentiating in dry eye [32] or Th17 cells per se are pathogenic in inflammatory disease [7,37,39],
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it would be better to use the Th17-associated dry eye model. In fact, NOD.B10.H2b mice, whose
autoreactive T cells contribute to pathogenesis, are available only from Jackson Laboratory. Because
we purchased NOD.B10.H2b from this source, where most of the mice lack Th17 cells in their immune
system compared with those from Taconic Laboratory, we could not see significant changes in IL-17
secreting T cells in our dry eye model unlike in the autoimmune uveitis model. Nevertheless, clinical
expression of the disease was attenuated accompanied by an increase of Treg cells and a decrease
of CD8+IFNγhi cells. In patients and in the NOD mouse model of Sjögren’s syndrome, lymphocytic
infiltrates are known to consist of CD4 and CD8 T cells in the lacrimal glands. However, the role
of CD8+ T cells in pathogenesis is still underexplored. A recent report showed that CD8+ T cells
contribute to the pathogenesis of lacrimal gland autoimmunity [40]. Adoptive transfer of CD8+ T
cells isolated from the NOD mice into NOD-SCID recipients resulted in inflammation of the lacrimal
glands regardless of the presence of CD4 T cells [40]. Given these observations, it seems reasonable
to hypothesize that the decrease of CD8+IFNγhi cells by IRT-5 may contribute to the improvement of
clinical dry eye manifestation that we observed. How exactly to down-regulate effector T cells in each
model is currently under investigation in our lab.
Gut microbiota appears to affect systemic disease in two different ways in animal models [17].
Type 1 diabetes in NOD mice is ameliorated by the presence of microbiota, and germ-free mice enhance
disease [41]. De Paiva et al. also reported that 24 days of treatment with broad spectrum antibiotics
tends to worsen dry eye with an increase of T cells [25]. On the contrary, the absence of microbiota
or alteration in its composition can attenuate expression of autoimmune diseases. Experimental
arthritis, EAE or EAU can be ameliorated in antibiotic-treated or germ-free mice [4,5,42]. Hori et al.
showed that depletion of the gut microbiota by treatment with broad-spectrum antibiotics which
had been given to pregnant dams and had continued after weaning (about 4 weeks) significantly
attenuated uveitis of R161H mice. That is, dysbiosis of intestinal microbiota may differently effect
on their autoimmunity depending on the disease entity or models. Considering that administration
of antibiotics diminishes preexisting microbiota in the gut, pre-treatment of antibiotics in our study
setting can be debated regarding the ascertain effect of antibiotics per se on disease expression. In fact,
the purpose of pre-treatment was to reduce pre-existing microorganism partially enough to get a space
for settling-down of the newly incoming IRT-5 commensals. However, we believe the pre-treatment
effect would be not detrimental because the application time was very short (5 days, Supplementary
Figure S2), and pre-treatment of antibiotics was done in both the control group and IRT-5-treated
group to reduce the bias.
5. Conclusions
In summary, our study suggests that IRT-5 probiotics may have a benefit to attenuate clinical
manifestation in EAU or autoimmune dry eye but not in alloimmunity of corneal transplantation.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/11/1166/s1,
Figure S1: Gating strategies for IFNγ or IL-17 secreting T cells (A), CD4+CD25+Foxp3hi T regulatory cells (Treg, B),
and monocytic Myeloid-Derived Suppressor Cells (mMDSC, C), Figure S2: In the EAU model, there were no
statistically significant differences in the percentage of IFNγ or IL-17 secreting T cells, and CD4+CD25+Foxp3hi T
regulatory cells among the total cervical lymph node (CLN) regardless of antibiotics pretreatment. AB stands for
antibiotics pre-treatment.
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